Eligibility for Semaglutide 2.4 mg in Patients With Acute Myocardial Infarction and Overweight or Obesity Without Diabetes: A Real-World Analysis

Despite advances in the prevention and management of cardiovascular (CV) disease, it still represents a significant disease burden, accounting for over 20% of all deaths in Australia [1]. Obesity is an independent and modifiable risk factor for CV disease [2]. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that, when combined with lifestyle modifications, results in an improvement in glycaemia and a reduction in body weight [3]. The recent Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial demonstrated that subcutaneous semaglutide 2.4 mg administered once weekly in patients with overweight and obesity without diabetes reduces the risk of death from CV causes by 20% compared with placebo after a mean follow-up of 33 months [4].